Stay updated on AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial page
- Check7 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check14 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
- Check36 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.3%
- Check65 days agoChange DetectedThe website has updated its results reporting with new dates and added detailed eligibility criteria for participants, including specific laboratory values and treatment history, while removing outdated status and previous reporting dates.SummaryDifference10%
- Check72 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study and includes a reference to the Contacts and Locations section.SummaryDifference4%
Stay in the know with updates to AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial page.